Partner Content Partner Content Next Generation Sequencing Market worth $15000 million by 20... Next Generation Sequencing Market to achieve 20% CAGR
News Could a Novo error set up early GLP-1 generics in Canada? Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
